Fecal microbiota transplantation in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials (2020-2025) - PubMed
4 days ago
- #Inflammatory Bowel Disease
- #Fecal microbiota transplantation
- #Meta-analysis
- Fecal microbiota transplantation (FMT) is a therapeutic strategy for Inflammatory Bowel Disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
- A systematic review and meta-analysis evaluated the efficacy and safety of FMT in IBD, analyzing RCTs published between 2020 and 2025.
- FMT showed significantly higher rates of clinical remission (OR = 3.24, 95% CI 1.43-7.41, p = 0.005) and endoscopic improvement (OR = 6.80, 95% CI 2.96-15.63, p < 0.0001) compared to controls.
- Serious adverse events were more common in FMT arms but not statistically significant (OR ~ 2.05, 95% CI 0.72-5.81, p = 0.18).
- Evidence for maintenance of remission was limited and inconsistent.
- FMT is effective for IBD, especially UC, but long-term efficacy and safety require further study through larger, well-designed RCTs.